Opinion Video Author(s): Panelists discuss how ritlecitinib, approved by the FDA in 2023 as the first Janus kinase (JAK) inhibitor for adolescents wit...

Opinion Video Author(s): Panelists discuss the key safety data observed with each of the three Janus kinase (JAK) inhibitors for alopecia areata (AA),...

ABSTRACT Semaglutide, a glucagon-like peptide-1 receptor agonist, is FDA approved under the brand names Ozempic for treatment of type 2 diabetes and W...

There are various types of cardiac rhythm monitors, each with distinct advantages and limitations related to cost, duration of monitoring, patient com...

Electronic health records (EHRs) have become integral to everyday clinical practice and hold significant potential as powerful tools for guiding diagn...

Bariatric surgery significantly decreased the likelihood of 5 obesity-related comorbidities compared with a weight loss management (WMP) program, a ne...

A June decision by the FDA to eliminate Risk Evaluation and Mitigation Strategies (REMS) for currently approved chimeric antigen receptor (CAR) T-cell...

The number of radiologists dedicating most of their clinical effort to pediatric imaging in the US has declined over the past decade, even as demand f...

There are key systemic factors crucial for ensuring broad access to new myasthenia gravis treatments, including guidelines and research, improved insu...

The safety and efficacy of first-line subcutaneous amivantamab plus chemotherapy for patients with EGFR exon 20 insertion–mutated advanced non–small c...